In a recent study posted to the Research Square preprint server, researchers assessed the impact of green tea catechin epigallocatechin gallate (EGCG) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
COVID-19 vaccine Phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint with robust neutralizing antibody titers similar to adults. Moderna is moving forward with
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its mRNA pipeline with two new development programs. This announcement reflects the Company's commitment to expanding its portfolio by building on Moderna's experience .